Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

K. Masago



Author of

  • +

    P1.10 - Poster Session 1 - Chemotherapy (ID 204)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P1.10-001 - Phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST study) (ID 124)

      09:30 - 09:30  |  Author(s): K. Masago

      • Abstract

      Background
      We report the interim-analysis result of the BEST trial, which examines efficacy and safety of second- or third-line chemotherapy with erlotinib (E) and bevacizumab (B) for the Japanese patients (pts) with non-squamous, non-small cell lung cancer.

      Methods
      E was administered initially at 150 mg/day orally and B was administered at a dose of 15 mg/kg on the first day of each 3-week cycle. The primary endpoint was objective response rate (RR). The secondary endpoints included overall survival (OS), progression-free survival (PFS), disease control rate (DCR) and incidence of adverse events. This trial was planned to accrue 80 pts based on a two-stage design employing a binomial distribution with an alternative hypothesis response rate of 35% and a null hypothesis threshold response rate of 20%. A subset analysis according to EGFR mutation status was planned (Trials. 2011; 12: 120).

      Results
      Total of 28 pts enrolled in 2 years from November, 2010. One patient was excluded due to thrombosis in lower limb and 27 pts (15 men and 12 women) with a median age of 67 (43-82) were analyzed; 18 pts had a PS of 0; all had adenocarcinoma; 11 pts had EGFR mutation; 1 patient had stage IIIB, 23 pts had stage IV and 3 pts had recurrences after surgery; 21 pts received as second-line and 6 pts received as third-line chemotherapy. RR was 18.5% (p=1.00; one-sided); DCR was 77.8%. Median PFS was 5.6 months (m); OS data were not yet mature (median follow-up time was 11.9 m). Grade 3/4 non-hematologic toxicities were mainly acne (11.1%) and hypertension (11.1%). The subset analysis according to EGFR showed significantly higher RR (p=0.02) and better PFS (p=0.03) in mutant group than in wild group. RR in mutant group was compared with 20% null hypothesis using the same binomial test (p=0.056).

      Conclusion
      Combination therapy of B and E had mild adverse effects but did not increase anti-cancer effect.

  • +

    P2.21 - Poster Session 2 - Diagnosis and Staging (ID 170)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Prevention & Epidemiology
    • Presentations: 1
    • +

      P2.21-007 - Computed tomography-guided needle aspiration and biopsy of pulmonary lesions: a single-center experience on 750 biopsies in Japan (ID 3288)

      09:30 - 09:30  |  Author(s): K. Masago

      • Abstract

      Background
      Computed tomography (CT)-guided fine needle aspiration (FNA) and biopsy is a well-established diagnostic method for pulmonary lesion.The aim of our study was to update the diagnostic outcomes and the safety profile of CT-guided lung biopsies.

      Methods
      We retrospectively analyzed the results of the CT -guided FNA and biopsies for 750 pulmonary lesions in 696 patients, and investigated the diagnostic yield, and complication rates.The independent risk factors for the diagnostic failure (ie, nondiagnostic, false-positive, and false-negative results) and the complications (severe pneumothorax) were determined using multivariate logistic regression analysis.

      Results
      The study included 417 male patients and 279 female patients, with a mean age of 71 years.The mean lesion size was 2.0 cm in maximal diameter.The biopsy results were nondiagnostic in 1.4% of the lesions (11 of 750 cases).The diagnostic accuracy was 92.6% (685/739cases).The sensitivity and specificity for the diagnosis of malignancy was 91.7% (534 of 582 cases) and 99.3% (156 of 157 cases), respectively.The significant independent risk factor for diagnostic failure was Lesions measuring < 2.0 cm (OR, 3.94; p <0.0001).Pneumothorax was the most common complication, and occurred in 36% (272 cases), pneumothorax requiring temporal drainage or chest tube insertion in 7.3% (55 cases), and tension pneumothorax, in 0.2% (2 cases).There were 27 cases (3.6%) with pulmonary hemorrhage, 63 cases (8.4%) with hemoptysis, 2 cases (0.2%) with air embolism , 5 cases (0.6%) with hypertension requiring antihypertensive treatment , 1 case (0.1%) with posterior reversible encephalopathy syndrome（PRES）, and 8 cases (1.0%) with others, including pain, shock, subcutaneous emphysema, subcutaneous hematoma, epilepsy, and bradycardia or tachycardia spell.From a total of 13 patients with severe complications, 12 patients recovered without sequela, however 1 patient recovered but developed paraplegia due to spinal cord infarction; there were no fatalities.The significant independent risk factors for pneumothorax requiring drainage were the depth from pleura < 3.0 cm (OR, 3.60; p <0.001), lesions in the middle lobe (OR, 2.25; p 0.0284),　and COPD patients(OR, 4.38; p <0.001).

      Conclusion
      CT-guided lung FNA and biopsy have a high diagnostic yield, but factors such as the acquisition of lesions measuring <2.0 cm significantly increased the rate of diagnostic failure.The complication rates were acceptable and comparable to previously published figures.The rate of pneumothorax requiring drainage was correlated with the depth from pleura < 3.0 cm, lesions in the middle lobe, and COPD patients.